drugset / Trial / NCT00291746

Validation of RDQ Questionnaire

NCT00291746

Phase 4 Completed 350 enrolled AstraZeneca
Non-randomizedSingle-groupSingle-blindDiagnostic

Summary

The primary objective of this study is to determine the accuracy of the Reflux Disease Questionnaire (RDQ) as a diagnostic test for gastroesophageal reflux disease. Symptom evaluation by the RDQ will be compared with other established approaches to the diagnosis of gastroesophageal reflux disease (GERD) in a primary care patient population with symptoms thought to be of upper gastrointestinal (GI) tract origin.

Timeline

Start
2005-09
Primary completion
Completion
2006-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Esomeprazole Small molecule 40 mg